BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data  Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BC Week In Review | Apr 12, 2019
Clinical News

Poxel's imeglimin meets in first Japanese Phase III for Type II diabetes

Poxel and Sumitomo said imeglimin met the primary endpoint in the Japanese Phase III TIMES 1 trial to treat Type II diabetes. The partners reiterated their plan to submit in 2020 an NDA to Japan’s...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Mar 9, 2018
Company News

Roivants new subsidiary adds Ligand asset

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which...
BC Extra | Mar 7, 2018
Company News

Roivant unveils new subsidiary on deal with Ligand

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which...
BC Week In Review | Feb 16, 2018
Company News

Poxel, Roivant partner for T2D in U.S., EU

Poxel S.A. (Euronext:POXEL) granted Roivant Sciences GmbH (Basel, Switzerland) rights to late-stage Type II diabetes candidate imeglimin (PXL008). Poxel will receive an upfront payment of $35 million and is eligible for up to $600 million...
BC Extra | Feb 12, 2018
Company News

Poxel finds U.S., European partner for imeglimin

Poxel S.A. (Euronext:POXEL) added €0.65 (10%) to €6.87 on Monday after granting Roivant Sciences GmbH (Basel, Switzerland) rights to late-stage Type II diabetes candidate imeglimin (PXL008). Poxel will receive an upfront payment of $35 million...
BC Week In Review | Jan 5, 2018
Clinical News

Poxel, Sumitomo launch Phase III program of imeglimin in diabebetes

Poxel S.A. (Euronext:POXEL) and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) began the double-blind, placebo-controlled, 24-week Japanese Phase III TIMES I trial of imeglimin (PXL008) to treat Type II diabetes. It is the first of three...
Items per page:
1 - 10 of 30